Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

SHANGHAI FOSUN PHARMACEUTICAL Aktie

 >FOSUN PHARMA Aktienkurs 
1.8435 EUR    (Tradegate)
Ask: 1.89 EUR / 3174 Stück
Bid: 1.797 EUR / 3341 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
FOSUN PHARMA Aktie über LYNX handeln
>FOSUN PHARMA Performance
1 Woche: +1,2%
1 Monat: +2,4%
3 Monate: +2,7%
6 Monate: +12,3%
1 Jahr: +17,5%
laufendes Jahr: +7,1%
>FOSUN PHARMA Aktie
Name:  SHANGHAI FOSUN PHARMACEUTICAL
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  CNE100001M79 / A1J68D
Symbol/ Ticker:  08HH (Frankfurt)
Kürzel:  FRA:08HH, ETR:08HH, 08HH:GR
Index:  -
Webseite:  https://www.fosunpharma.c..
Marktkapitalisierung:  7470 Mio. EUR
Umsatz:  35391.01 Mio. EUR
EBITDA:  4510.53 Mio. EUR
Gewinn je Aktie:  0.114 EUR
Schulden:  31810.66 Mio. EUR
Liquide Mittel:  14102 Mio. EUR
Umsatz-/ Gewinnwachstum:  -7.3% / 25.4%
KGV/ KGV lG:  14.04 / 10.66
KUV/ KBV/ PEG:  1.02 / 0.86 / -
Gewinnm./ Eigenkapitalr.:  7.25% / 6.2%
Dividende je Aktie:  0.035 EUR
Dividendenrendite/ -schätzung:  1.9% / 1.84%
Div. Historie:  26.07.24 - 0.03543€
31.07.23 - 0.05354€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  SHANGHAI FOSUN PHARMACEUTICAL, SHANGHAI FOSUN PHARMA, FOSUN PHARMA
Letzte Datenerhebung:  05.07.25
>FOSUN PHARMA Eigentümer
Aktien: 551.94 Mio. St.
f.h. Aktien: 1660 Mio. St.
Insider Eigner: 14.41%
Instit. Eigner: 15.37%
Leerverk. Aktien: -
>FOSUN PHARMA Peer Group

 
26.06.25 - 12:57
Fosun Pharma prices $34.25M Nature’s Sunshine share sale (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.06.25 - 12:33
Nature′s Sunshine Products, Inc. Announces Pricing of Secondary Public Offering of Common Stock (GlobeNewswire EN)
 
LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions....
25.06.25 - 22:03
Nature′s Sunshine Products, Inc. Announces Launch of Secondary Public Offering of Common Stock (GlobeNewswire EN)
 
LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”)....
16.06.25 - 15:30
Teva, Shanghai Fosun Partner To Develop TEV-56278 (AFX)
 
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278 ut......
16.06.25 - 15:06
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology (PR Newswire)
 
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages......
06.06.25 - 11:15
FOSUN PHARMA Repurchases 800K A-Shrs, Involving ~RMB20M (AAStocks)
 
FOSUN PHARMA (02196.HK)(600196.SH) announced that it repurchased a total of 800,300 shares of the company on the Shanghai Stock Exchange today (6th), with the price per share ranging from RMB24.92 to RMB25.14, involving a total of approximately RMB19.9988 million. ~AASTOCKS Financial NewsWebsite: www.aastocks.com...
30.05.25 - 09:15
FOSUN PHARMA Once Surges 10%+; Subsidiary's Luvometinib Tablets Receives Drug Registration Approval (AAStocks)
 
FOSUN PHARMA (02196.HK) opened up 2.27% today (30th) and once surged by 10.3% to a peak of HKD16.5. It last traded at HKD16.38, up 9.49%, on a volume of 30.4045 million shares, involving HKD488 million.Shanghai Fosun Pharmaceutical Industrial, a subsidiary of Fosun Pharmaceutical, has received approval from China's National ......
12.05.25 - 07:15
Research: Citi Lists H-shrs w/ US Exports (Table) (AAStocks)
 
Stock│Forecast for Percentage of Revenue from Export to US in 2025COWELL (01415.HK)│30%ASMPT(00522.HK)│15%BYD ELECTRONIC (00285.HK)│around 25-30%.KLN (00636.HK)│15-20%AAC TECH (02018.HK)│12%FOSUN PHARMA (02196.HK)│11%SUNNY OPTICAL (02382.HK)│9%Q TECH (01478.HK)│<1%CHERVON ......
29.04.25 - 03:45
FOSUN PHARMA Clinches Strategic Partnership with Fakeeh Care Group to Extend Product Reach to Mideast (AAStocks)
 
FOSUN PHARMA (02196.HK) announced a strategic partnership with Saudi Arabia’s Fakeeh Care Group, an integrated healthcare group, to jointly promote biologics, CAR-T cell therapies, and other cutting-edge treatments in Saudi Arabia, accelerating local medical innovation. Guo Guangchang, Chairman of Fosun International, expr......
27.03.25 - 15:37
Shanghai Fosun Pharmaceutical reports FY results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.03.25 - 03:30
Fosun Pharma Announces 2024 Annual Results (PR Newswire)
 
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global......
14.03.25 - 15:18
Fosun Pharma to sell $124m stake in hospital chain to Warburg Pincus (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
26.02.25 - 13:03
Tenapanor Approved in China for Hyperphosphatemia (GlobeNewswire EN)
 
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval...
26.02.25 - 11:36
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets) (PR Newswire)
 
Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial......
17.02.25 - 03:30
FOSUN PHARMA Self-developed PharmAID Decision Agent Platform Links to Deepseek R1 (AAStocks)
 
FOSUN PHARMA (02196.HK) recently released internally its self-developed PharmAID decision agent platform, which is currently constructing a full lifecycle intelligent decision-making network covering innovative R&D scenarios, according to FOSUN PHARMA. The platform deeply integrates the world's leading foundation model t......
20.11.24 - 03:45
IPO: JIUYUAN GENE (02566.HK) Entry Fee $2,537.33, Introduces FOSUN PHARMA, ALI HEALTH as Cornerstone Investors (AAStocks)
 
Chinese biopharmaceutical company JIUYUAN GENE (02566.HK) announced the details of its offering. It proposed to offer 45.3988 million shares globally, of which about 10% will be offered in Hong Kong and about 90% will be offered internationally. The offer price ranges from $11.48 to $12.56 per share.The entry fee is $2,537.33 fo......
30.10.24 - 03:43
Fosun Pharma Announces 2024Q3 Financial Results (PR Newswire)
 
Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the......
28.08.24 - 12:12
Fosun Pharma Announces 2024 Interim Results (PR Newswire)
 
Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK),......
25.07.24 - 23:49
XFRA : DIVIDEND/INTEREST INFORMATION - 26.07.2024 - CNE100001M79 (XETRA)
 
Das Instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY wird ex Dividende/Zinsen gehandelt am 26.07.2024 The instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY has its ex-dividend/interest day on 26.07.2024...
25.07.24 - 00:08
XFRA : DIVIDEND/INTEREST INFORMATION - 26.07.2024 - CNE100001M79 (XETRA)
 
Das Instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY wird cum Dividende/Zinsen gehandelt am 25.07.2024 und ex Dividende/Zinsen am 26.07.2024 The instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY has its pre-dividend/interest day on 25.07.2024 and its ex-dividend/interest day on 26.07.2024...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!